Articles On Race Oncology (ASX:RAC)

Title Source Codes Date
ASX healthcare stock surges 11% on 'incredibly valuable' FDA news

Race Oncology Ltd (ASX: RAC) shares are roaring higher on Tuesday morning. In early trade, the ASX healthcare stock is up 11% to $1.94. Why is this ASX healthcare stock surging? Investors have been buying the clinical stage biopharmaceutica...

Motley Fool RAC 1 hour ago
Race delivers promising results in cancer drug mice research into heart complications

Race Oncology (ASX:RAC) has announced a preclinical breakthrough in heart toxicity side effects caused by the carfilzomib, which had precluded the drug being administered to patients diagnosed with elevated cardiac risk factors. In work...

themarketonline.com.au RAC 5 days ago
Race says bisantrene highly active in a mouse model of multiple myeloma

Race Oncology (ASX:RAC) has reported the results of preclinical work performed under contract by US-based Labcorp of a mouse model involving bisantrene in combination with carfilzomib.

BiotechDispatch RAC 5 days ago
Here are the top 10 ASX 200 shares today

The S&P/ASX 200 Index (ASX: XJO) endured a horror return for the short trading week this Tuesday, crashing by a depressing 1.33%. By the time the market closed, the ASX 200 was sittin...

Motley Fool RAC 6 days ago
Closing Bell: ASX buried under -1.3pc as iron ore miners and goldies take a beating

Aussie shares slipped over 1pc after the King’s Birthday long weekend Mining and Real Estate sectors were the biggest losers among all 11 sectors Chinese EV stocks fell ahead of expected EU tariff hikes   Aussie shares slipped after the K...

Stockhead RAC 6 days ago
US FDA extends orphan drug designation for Race Oncology’s lead asset

  US FDA extends orphan drug designation to Race’s re-formulated RC220 bisantrene drug product for treatment of Acute Myeloid Leukemia Orphan drug designation has a range of commercial advantages including seven years market exclusivity in...

Stockhead RAC 6 days ago
Meet Apple's new $186 billion market opportunity

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Some might think Apple Inc's (NASDAQ: AAPL) best days are behind it. Revenue growth has ground to a halt. The company's bigge...

Motley Fool RAC 6 days ago
Why Arizona Lithium, Bapcor, Race Oncology, and Tower shares are pushing higher

The S&P/ASX 200 Index (ASX: XJO) is having a very tough start to the week. In afternoon trade, the benchmark index is down 1.45% to 7,745.6 points. Four ASX shares that are not letting that hold them back today are listed below. Here's...

Motley Fool RAC 6 days ago
ASX Health Stocks: Orthocell seeks TGA approval; Race Oncology gets FDA nod

Orthocell (ASX:OCC) has taken a significant step forward in its efforts to introduce its SmrtGraft product to the Australian market. The company has submitted an application to the Therapeutic Goods Administration (TGA) seeking approval to...

Stockhead RAC 6 days ago
Guess which ASX 200 share just rocketed 15% on a $1.8 billion takeover offer

The S&P/ASX 200 Index (ASX: XJO) is down 1.1% today, but you can't blame this rocketing ASX 200 share. Shares in the auto parts company closed on Friday trading for $4.36. In earlier trade on Tuesday, shares were swapping hands for $...

Motley Fool RAC 1 week ago
Race Oncology’s bisantrene RC220 AML treatment earns coveted FDA orphan drug designation

Race Oncology (ASX: RAC) has achieved a significant breakthrough with the US Food and Drug Administration (FDA) awarding orphan drug designation (ODD) to the company’s acute myeloid leukemia (AML) candidate bisantrene RC220. The coveted des...

SmallCaps RAC 1 week ago
Analysts name 2 ASX dividend shares to buy now

Deciding which ASX dividend shares to buy can be a gruelling process. Luckily for income investors, analysts have done a lot of the hard work for you and picked out two they think are buys. Here's what they are saying about these dividend s...

Motley Fool RAC 2 weeks ago
Only 1 ASX 200 bank share delivers more capital growth than dividends. Which bank? (Clue: Not CBA)

Investors tend to consider ASX 200 bank shares as dividend payers rather than growth investments, with two exceptions — Commonwealth Bank of Australia (ASX: CBA) and Macquarie Group Ltd (ASX: MQG). And there's good reason for those excep...

Motley Fool RAC 2 weeks ago
Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

The work of pharmaceutical companies can bring new hope to patients delivering solutions to unmet medical needs. It can also turn a small market cap play into a giant – but it’s a process that’s not easy, it’s risky and it can take a lot of...

themarketonline.com.au RAC 3 weeks ago
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead RAC 3 weeks ago
These ASX 200 shares could rise 15% to 50%

Investors that are on the lookout for some big returns might want to check out these ASX 200 shares listed below. That's because analysts are tipping their shares to deliver returns of between 15% and 50% for investors over the next 12 mont...

Motley Fool RAC 4 weeks ago
Macquarie ups the ante on fees with new ASX ETFs

The conventional wisdom on the ASX exchange-traded fund (ETF) landscape is that index funds offer investors the lowest fees. Amongst all ETFs on the Australian markets, the lowest charging are all index funds that cover either ASX or Americ...

Motley Fool RAC 1 month ago
Market Close: ASX signs off slightly down with some red blushes

The ASX200 closed the day down 0.3 of a per cent. Aside from consumer discretionary and healthcare, all other sectors ended in the red. The latest data from ANZ on Australian consumer spending shows that activity has increased 5.7% ov...

themarketonline.com.au RAC 1 month ago
Here are the top 10 ASX 200 shares today

It was a dastardly Tuesday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares during today's trading. The ASX 200 finished up with its tail between its legs...

Motley Fool RAC 1 month ago
Closing Bell: Copper stocks are rolling, but not the ASX ahead of Federal Budget and US inflation

ASX retreats on Tuesday ahead of Fed Budget and US PPI/CPI Copper stocks up after the metal hit highest level since 2022 GUD jumps 11pc after strong FY24 update   The ASX dipped by -0.4% on Tuesday ahead of the Federal Budget and a key PP...

Stockhead RAC 1 month ago
What should be in tonight's Budget

G'day Treasurer, I'm glad I've caught you in time. I know you have a Budget to hand down in a few hours. And I know it's already printed, so it's a bit late to make changes. But I know you're a good man, and you want to make sure you've lef...

Motley Fool RAC 1 month ago
Combining Race’s bisantrene with decitabine enhances cancer-cell killing abilities, study shows

Bisantrene and decitabine used together offer significantly improved cancer cell-killing across 143 tumour cell lines than either drug used alone Results support the use of decitabine in combination with bisantrene as a potential new treat...

Stockhead RAC 1 month ago
Why Credit Corp, GUD, Race Oncology, and Spartan Resources shares are rising

The S&P/ASX 200 Index (ASX: XJO) is having a tough session on Tuesday. In afternoon trade, the benchmark index is down 0.4% to 7,719.1 points. Four ASX shares that are not letting that hold them back today are listed below. Here's why...

Motley Fool RAC 1 month ago
Market Update: ASX pales but health looks rosy

The ASX200 is tracking lower than expected, down nearly a quarter of a per cent. The health care sector is leading intraday gains, up more than 0.5%. Real estate has fallen the most, down around 0.8%, Staples follows closely behind down...

themarketonline.com.au RAC 1 month ago
2 ASX healthcare shares rocking higher on big news

ASX healthcare shares are one of only two market sectors trading in the green at the time of writing. The S&P/ASX 200 Health Care Index (ASX: XHJ) is up 0.55% and is the best sector of the day so far. These two ASX healthcare sha...

Motley Fool RAC 1 month ago
Invest in quality, not meme stocks

One of my personal investing mottos is "the market is straight up kooky dooks". Not only did I think of this saying again today, I also felt it fitting that it was paraphrased from a movie – in this case the Disney (NYSE: DIS) animated...

Motley Fool RAC 1 month ago
ASX Health Stocks: RAC says combining lead drug bisantrene with decitabine is effective on solid tumours

Race Oncology says bisantrene + decitabine effective Race Oncology (ASX:RAC) jumped 8% this morning after sharing the results from recent preclinical studies conducted at Oncolines B.V. in the Netherlands. In these studies, bisantrene (Race...

Stockhead RAC 1 month ago
Why this $1.5 billion ASX 200 stock just surged 10%

S&P/ASX 200 Index (ASX: XJO) stock GUD Holdings Ltd (ASX: GUD) is off to the races on Tuesday. Shares in the diversified automotive market products company closed yesterday trading for $9.77. At the time of writing in late morning tr...

Motley Fool RAC 1 month ago
Race shares the results of preclinical studies combining bisantrene with decitabine

Race Oncology (ASX:RAC) has shared the results from recent preclinical work performed under contract at Oncolines in the Netherlands, combining bisantrene with decitabine.

BiotechDispatch RAC 1 month ago
Race Oncology reports “enhancement” of cancer cell-killing capabilities

Race Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed Phase I/II leukaemia trial. That enhance...

themarketonline.com.au RAC 1 month ago
Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed Phase I/II leukaemia trial. That enhance...

themarketonline.com.au RAC 1 month ago
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Stockhead RAC 1 month ago
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Stockhead RAC 1 month ago
Which ASX companies are resurrecting abandoned drugs? Part 3

Several ASX companies are repurposing or resurrecting abandoned or under utilised drugs  Paradigm Biopharmaceuticals identified the potential of FDA-approved PPS that has a long track record of treating inflammation Starpharma has develope...

Stockhead RAC 2 months ago
Dr Boreham’s Crucible: Race Oncology

By Tim Boreham ASX code: Race Oncology ((RAC)) Shares on issue: 164,778,179 Market cap: $237.3m Financials (December half 2023): revenue nil, loss of -$5.66m (-$4.41m deficit previously), cash of $13.7m (down -48%). During the period the co...

FNArena RAC 2 months ago
WTF with Race Oncology: Changing the chemo game

What is traditional chemotherapy? How is Race Oncology trying to change it? What are the alternative cancer treatments? Race Oncology (ASX:RAC) chief executive Dr Daniel Tillett joins the Stockhead TV studio to investigate these questions a...

Stockhead RAC 2 months ago
Race Oncology achieves ‘major milestone’ in progress of lead drug to human trials

Race Oncology says certificate of analysis issued by Ardena for first cGMP batch of bisantrene formulation RC220 Confirms RC220 meets all cGMP specifications required for a human IV drug product Company says major milestone in the progre...

Stockhead RAC 2 months ago
Market Close: ASX closes flattish with IT in the red and energy making marginal gains

The ASX200 closed the day down .4 of a per cent, with IT stocks weighing on the market and energy leading the pack with marginal gains at the other end of the spectrum. The Energy sector tipped the field into positive territory, closing...

themarketonline.com.au RAC 2 months ago
Closing Bell: Tech stocks drag ASX lower; Mesoblast jumps 50pc after all-clear from FDA

The ASX 200 slipped by -0.3% on Tuesday, tracking movements on Wall Street overnight.  The local market was dragged down by profit taking in the Tech and Comm Services sectors, while Energy was the only one to close in the green. Advancers...

Stockhead RAC 2 months ago
Race Oncology’s latest chemotherapy drug ‘RC220’ gets go-ahead

Race Oncology (ASX: RAC) has made further progress in the development of its proprietary bisantrene formulation drug, RC220 – whereby a Certificate of Analysis (CoA) for the first current Good Manufacturing Practice (cGMP) batch has been is...

themarketonline.com.au RAC 2 months ago
'Reaching this point in the development of bisantrene is a major milestone and accomplishment'

Race Oncology (ASX:RAC) has announced that a Certificate of Analysis has been issued for the first current Good Manufacturing Practice batch of its proprietary bisantrene formulation, RC220.

BiotechDispatch RAC 2 months ago
ASX Today: Stocks Hot Copper users are watching pre-market on Tuesday

Mineral Resources (MIN) has updated on the Lockyer-5 gas well. The Kingia Sandstone target downhole the Perth Basin asset was successfully hit at 4.2km depth. Wireline logs revealed 27m of net gas pay with porosity of 18%. Shares...

themarketonline.com.au RAC 2 months ago
Guess which ASX All Ords share is surging 16% after announcing a new finance chief

Race Oncology Ltd (ASX: RAC) shares are on form and racing higher on Monday. In afternoon trade, the ASX All Ords share is up over 16% to $1.81. This means that the oncology company's shares are now up an impressive 130% since this time la...

Motley Fool RAC 2 months ago
Closing Bell: ASX a little lower after hosting a Big 4 bank midweek spank

Local markets end lower on big bank sell-off Material gains offset by Telco’s and Financials  Small Caps led by rare earths developer Arafura   Local markets have not showered anyone in glory, profit or confidence on Thursday. At 4pm on T...

Stockhead RAC 3 months ago
International cardiometabolic expert to join Race Oncology’s scientific advisory board

Race Oncology appoints Associate Professor Erin Howden to scientific advisory board Howden has researched adverse effects of chemotherapy on cardiovascular fitness of cancer patients Appointment aims to bring Race Oncology’s new formulatio...

Stockhead RAC 3 months ago
Market Highlights: Wall Street’s mixed as oil rises, copper flies and the crunch comes for iron ore

ASX looks set rise after mixed session on Wall street overnight Momentum in the tech sector wanes; Tesla cops a downgrade Oil prices rise, iron ore under pressure and copper prices surge  The ASX looks set to rise on Thursday morning. The...

Stockhead RAC 3 months ago
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 1

It’s been a tough couple of years for ASX health care with challenging economic conditions including steep interest rates rises to combat soaring inflation hitting the sector like a nasty dose of influenza. Furthermore, a frenzy around the...

Stockhead RAC 3 months ago
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Stockhead RAC 3 months ago
Market Update: ASX falls further than expected; Q4 GDP growth at 0.2%

The ASX200’s been trading down a quarter of a per cent – even further than expected.  The utilities and financials sectors are in the lead – up around 0.4 of a per cent, while IT is lagging  – down more than 2 per cent. Australia’s Gr...

themarketonline.com.au RAC 3 months ago
ASX Health Stocks: Atomo pops 90pc after purchase order; AdAlta up 20pc on Phase 1 results

Atomo jumps 90pc after reporting a significant sales order AdAlta up 20pc after revealing key results from Phase 1 study Race Oncology’s drug shows potent anticancer activity    Atomo up 90pc on HIV kit sales Atomo Diagnostics (ASX:AT1)...

Stockhead RAC 3 months ago